

Anti-Complement component C1 inhibitor (human, C1INH)**Mouse monoclonal antibody**Subclass: IgG₁/k

CAT. NO.

HYB 288-05

Clone: 8 F3

SPECIFICITY	HYB 288-05 is specific for human C1INH.
IMMUNOGEN	C1-inhibitor (C1INH) isolated from human plasma
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Epitope specificity differs from that of HYB 288-02

PRESENTATION

Content:	Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION	ELISA: HYB 288-05 reacts strongly with C1-INH. A strong reaction is seen with human serum/plasma when tested in sandwich ELISA in combination with a polyclonal antibody against C1-INH, and in ELISA with C1-INH coated directly onto the microtiter well.
-------------	--

TARGET	C1-inhibitor (C1INH) functions as a regulator of the activation of the classical complement pathway and of the contact activation system of kinin generation and coagulation. Its primary biologically relevant target proteinases are C1r, C1s, coagulation factors XIa and XIIa, and plasma kallikrein. C1-inhibitor consists of one polypeptide chain and has a molecular mass of 104 kDa. Serum concentration has been determined to 180 µg/ml.
--------	---

REFERENCES**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.